EA200401256A1 - (5R)-5-(МЕТИЛАМИНО)-5,6-ДИГИДРО-4H-ИМИДАЗО[4,5,1-ij]ХИНОЛИН-2(1H)-ТИОН ИЛИ ЕГО СОЛЬ И СПОСОБ ЕГО ПОЛУЧЕНИЯ - Google Patents

(5R)-5-(МЕТИЛАМИНО)-5,6-ДИГИДРО-4H-ИМИДАЗО[4,5,1-ij]ХИНОЛИН-2(1H)-ТИОН ИЛИ ЕГО СОЛЬ И СПОСОБ ЕГО ПОЛУЧЕНИЯ

Info

Publication number
EA200401256A1
EA200401256A1 EA200401256A EA200401256A EA200401256A1 EA 200401256 A1 EA200401256 A1 EA 200401256A1 EA 200401256 A EA200401256 A EA 200401256A EA 200401256 A EA200401256 A EA 200401256A EA 200401256 A1 EA200401256 A1 EA 200401256A1
Authority
EA
Eurasian Patent Office
Prior art keywords
imidazo
dihydro
quinolin
ionion
metylamino
Prior art date
Application number
EA200401256A
Other languages
English (en)
Inventor
Брэд А. Экер
Ричард Ф. Хайер
Алан К. Джин
Мальколм В. Мун
Original Assignee
Фармация Энд Апджон Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармация Энд Апджон Компани filed Critical Фармация Энд Апджон Компани
Publication of EA200401256A1 publication Critical patent/EA200401256A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение представляет (5R)-5-(метиламино)-5,6-дигидро-4H-имидазо[4,5,1-ij]хинолин-2(1H)-тион или его фармацевтически приемлемую соль и способ его получения, включающий взаимодействие (5R)-(метиламино)-5,6-дигидро-4H-имидазо[4,5,1-ij]хинолин-2(1H)-она с декасульфидом тетрафосфора; предпочтительно указанное взаимодействие осуществляют при температуре около 125°C и в присутствии пиридина в качестве растворителя. Указанное соединение полезно для лечения сексуальных нарушений у людей и стимуляции спаривания у млекопитающих.
EA200401256A 1999-01-06 1999-12-20 (5R)-5-(МЕТИЛАМИНО)-5,6-ДИГИДРО-4H-ИМИДАЗО[4,5,1-ij]ХИНОЛИН-2(1H)-ТИОН ИЛИ ЕГО СОЛЬ И СПОСОБ ЕГО ПОЛУЧЕНИЯ EA200401256A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11484099P 1999-01-06 1999-01-06
US11505199P 1999-01-08 1999-01-08
US11592299P 1999-01-14 1999-01-14
US12054399P 1999-02-17 1999-02-17

Publications (1)

Publication Number Publication Date
EA200401256A1 true EA200401256A1 (ru) 2005-12-29

Family

ID=27493976

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200100750A EA005412B1 (ru) 1999-01-06 1999-12-20 Способ лечения сексуальных нарушений
EA200401256A EA200401256A1 (ru) 1999-01-06 1999-12-20 (5R)-5-(МЕТИЛАМИНО)-5,6-ДИГИДРО-4H-ИМИДАЗО[4,5,1-ij]ХИНОЛИН-2(1H)-ТИОН ИЛИ ЕГО СОЛЬ И СПОСОБ ЕГО ПОЛУЧЕНИЯ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200100750A EA005412B1 (ru) 1999-01-06 1999-12-20 Способ лечения сексуальных нарушений

Country Status (20)

Country Link
US (9) US6455564B1 (ru)
EP (1) EP1140092A2 (ru)
JP (1) JP2002534376A (ru)
KR (1) KR20010089779A (ru)
CN (1) CN1332628A (ru)
AU (1) AU782596B2 (ru)
BR (1) BR9916759A (ru)
CA (1) CA2350946A1 (ru)
CO (1) CO5150156A1 (ru)
CZ (1) CZ20012459A3 (ru)
EA (2) EA005412B1 (ru)
HK (1) HK1041812A1 (ru)
HU (1) HUP0105036A3 (ru)
ID (1) ID30276A (ru)
IL (1) IL144172A0 (ru)
NZ (1) NZ512820A (ru)
PE (1) PE20001374A1 (ru)
SK (1) SK7732001A3 (ru)
TR (1) TR200101895T2 (ru)
WO (1) WO2000040226A2 (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
AU767089B2 (en) * 1999-02-05 2003-10-30 Pharmacia & Upjohn Company Process to prepare (5R)-(methylamino)-5,6-dihydro-4H- imidazo(4,5,1-ij)-quinolin-2(1H)-one
US7258850B2 (en) 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
EP1175204A4 (en) * 1999-05-04 2006-05-31 Aradigm Corp AEROSOL FORMULATION AND ARTICLES FOR INCREASING LIBIDO IN WOMEN BY MOMENTARY TESTOSTERONE ADMINISTRATION
WO2001000221A2 (en) * 1999-06-23 2001-01-04 Institut Pasteur Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
CN1450898A (zh) 2000-04-21 2003-10-22 法玛西雅厄普约翰美国公司 用于治疗纤维肌痛和慢性疲劳综合症的化合物
AR033520A1 (es) * 2000-04-27 2003-12-26 Upjohn Co (5r)-(metilamino) -5,6-dihidro-4h-imidazo[4,5,1-ij] quinolin-2(1h)-tiona
AR031152A1 (es) 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
EP1365740A1 (en) * 2001-02-08 2003-12-03 Pharmacia Corporation Rapid-onset medicament for the treatment of sexual dysfunction
US20030073609A1 (en) 2001-06-29 2003-04-17 Pinkerton Thomas C. Enhanced pharmacokinetic profile of intradermally delivered substances
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
SE0202365D0 (sv) * 2002-08-05 2002-08-05 Pharmacia Ab New formulation and use thereof
US7037257B1 (en) * 2002-08-22 2006-05-02 Koenig J Frank Erectile dysfuction treatments comprising momentary vacuum therapy alone or with medications
EP1545521A2 (en) * 2002-10-04 2005-06-29 Pharmacia Corporation Compositions and methods for treating sexual dysfunction
EP1546120A4 (en) * 2002-10-04 2006-11-22 Pharmacia Corp PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE
CA2536874A1 (en) * 2003-09-05 2005-03-17 Novartis Ag Compositions comprising benzo (g) quinoline derivatives and prostaglandin derivatives
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
JP2009502961A (ja) 2005-07-29 2009-01-29 コンサート ファーマシューティカルズ インコーポレイテッド 新規な医薬組成物
WO2007033239A2 (en) * 2005-09-13 2007-03-22 Elan Pharma International, Limited Nanoparticulate tadalafil formulations
US7615075B2 (en) * 2005-11-04 2009-11-10 Rush University Medical Center Plastic implant impregnated with a degradation protector
US20080004310A1 (en) * 2006-06-19 2008-01-03 Applied Pharmacy Services, Inc. Lyophilized pharmaceutical composition
WO2017100324A1 (en) * 2015-12-10 2017-06-15 Repros Therapeutics Inc. Combination therapy for treating female hypoactive sexual desire disorders
WO2019055877A1 (en) 2017-09-15 2019-03-21 Forma Therapeutics, Inc. TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
KR20250067962A (ko) 2018-06-29 2025-05-15 포르마 세라퓨틱스 인크. Creb 결합 단백질(cbp)의 저해
EP3937936A4 (en) * 2019-03-15 2022-12-28 Forma Therapeutics, Inc. INHIBITION OF CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB)
US12351577B2 (en) 2019-03-15 2025-07-08 Forma Therapeutics, Inc. Inhibiting cyclic AMP-responsive element-binding protein (CREB)
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
EP4039746A1 (de) 2021-02-08 2022-08-10 Covestro Deutschland AG Polycarbonat-polyester zusammensetzung, formmasse und formkörper mit guter schlagzähigkeit und hoher thermischer belastbarkeit

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127118B1 (en) 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4801587A (en) 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US4935514A (en) * 1989-06-06 1990-06-19 Ethyl Corporation Thiation process
US5273975A (en) * 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
ES2067744T3 (es) * 1989-06-09 1995-04-01 Upjohn Co Aminas heterociclicas con actividad sobre el sistema nervioso central.
US5242391A (en) 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5541211A (en) 1991-06-18 1996-07-30 Orion-Yhtyma Oy Administration of atipamezole to elicit a yohimbine-like alpha-adrenoreceptor antagonistic noradrenergic transmission
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
CA2166700C (en) * 1993-07-27 2000-04-18 Arthur G. Romero Heterocyclic amines having central nervous system activity
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
CA2188385C (en) 1994-04-22 2000-07-11 Ragab El-Rashidy Dosage forms and method for ameliorating male erectile dysfunction
EP0985671B1 (en) * 1996-05-31 2003-04-02 Mochida Pharmaceutical Co., Ltd. PYRIDOCARBAZOLE DERIVATIVES HAVING cGMP-PDE INHIBITORY EFFECT
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances

Also Published As

Publication number Publication date
HK1041812A1 (zh) 2002-07-26
US6809112B2 (en) 2004-10-26
US20020198187A1 (en) 2002-12-26
CA2350946A1 (en) 2000-07-13
US20040214826A1 (en) 2004-10-28
US20040214825A1 (en) 2004-10-28
WO2000040226A3 (en) 2001-02-01
CO5150156A1 (es) 2002-04-29
CN1332628A (zh) 2002-01-23
AU782596B2 (en) 2005-08-11
WO2000040226A2 (en) 2000-07-13
NZ512820A (en) 2002-12-20
JP2002534376A (ja) 2002-10-15
EA200100750A1 (ru) 2001-12-24
US20030013710A1 (en) 2003-01-16
BR9916759A (pt) 2001-09-25
US20030004152A1 (en) 2003-01-02
US6903127B2 (en) 2005-06-07
US20020107247A1 (en) 2002-08-08
SK7732001A3 (en) 2001-12-03
CZ20012459A3 (cs) 2002-01-16
EA005412B1 (ru) 2005-02-24
AU2348200A (en) 2000-07-24
EP1140092A2 (en) 2001-10-10
KR20010089779A (ko) 2001-10-08
US20040214824A1 (en) 2004-10-28
TR200101895T2 (tr) 2001-12-21
US6921771B2 (en) 2005-07-26
PE20001374A1 (es) 2000-11-19
HUP0105036A3 (en) 2002-10-28
ID30276A (id) 2001-11-15
US6455564B1 (en) 2002-09-24
IL144172A0 (en) 2002-05-23
HUP0105036A2 (hu) 2002-05-29
US6890945B2 (en) 2005-05-10
US20040214823A1 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
DE69830503D1 (de) Tablette mit verlängerter wirkstoffabgabe zur behandlung der parkinsonkrankheit
US6656945B2 (en) 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction
KR920701204A (ko) 중추 신경계 활성을 갖는 헤테로사이클릭 아민
NZ512820A (en) (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione useful for treating sexual disturbances
NO178766C (no) Analogifremgangsmåte for fremstilling av benzodiazepin og mellomprodukter derav
ES2185808T3 (es) Procedimiento para preparar tetrahidroimidazoquinolinaminas.
WO2002094830A8 (en) Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists
WO2003020698A3 (en) Protein tyrosine kinase inhibitors
NO974603D0 (no) Anvendelse av imidazo£1,2-a|pyridin-3-acetamidderivater for terapeutisk behandling av neuropsykiatriske syndromer assosiert med disfunksjon av de sentrale områder av de basale ganglia
BR0309463A (pt) Derivados de 1,2,3,4,7,8-hexaidro-6h-[1,4]diazepino[6,7,1-ij]quinolina como agentes antipsicóticos e antiobesidade
ES2078559T3 (es) Procedimiento para la preparacion de hidrocloruro de 3-amino-9,13b-dihidro-1h-dibenz(c,f)imidazo(1,5-a)azepina.
NO20013645D0 (no) Anvendelse av pyridazino[4,5-b]indol-1-acetamid-derivater for fremstilling av medisiner for behandling av sykdommer relatert tildysfunksjonen av perifere benzodiazepinreseptorer
NO20013334L (no) Anvendelse av imidazo [1,5-A]-pyrido[3,2-E]-pyrazinoner som legemidler
FR2719843B1 (fr) Dérivés de 5,6-dihydro-4h-imidazo [2',1':2,3] imidazo-[4,5,1-ij] quinoléine et de 4,5-dihydroimidazo [1,2-a] pyrrolo-[1,2,3-cd] benzimidazole, leur préparation et leur application en thérapeutique.
NZ515882A (en) Treatment of serotonin related disorders with 2,7-substituted octahydro-1H-pyrido[1,2-a]pyrazine derivatives
ATE242242T1 (de) Derivate von imidazo(1,2-a)pyridin zur behandlung von gastrointestinalen krankheiten
ATE256126T1 (de) 5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen
PL349912A1 (en) Process to prepare (5r)-(methylamino)-5,6-dihydro-4h-imidazo[4,5,1-ij]-quinolin-2(1h)-one
AR033520A1 (es) (5r)-(metilamino) -5,6-dihidro-4h-imidazo[4,5,1-ij] quinolin-2(1h)-tiona
AU4556999A (en) Pyrido[2,3-b]indolizine derivatives and aza analogues thereof; crf1 specific ligands
WO2004071391A3 (en) Imidazopyridines containing combinations and their use in treating gastrointestinal inflammatory disorders
EE200100700A (et) Asendatud [1,4]diasepino[6,7,1-hi]indool-4-oonidevalmistamismeetod
RU2021123936A (ru) Пентациклическое гетероциклическое соединение
RU2006102587A (ru) Применение циклических биоизостеров производных пуриновой системы для лечения расстройств, вызванных нарушениями нитрергической и дофаминергической систем
TH56142A3 (th) อนุพันธ์ของไตรอะโซโล-ไพริดาซีนเป็นลิแกนด์สำหรับ gaba รีเซพเตอร์